Enhancing effect of a modified yeast mannan on antitumor activity of mitomycin-C.
A synthetic stearolymannan phosphate designated as SMP-Fr. I-d, consisting of three components, fatty acid, polysaccharide, and phosphate, enhanced the therapeutic effect of Mitomycin-C in mice implanted with 1 x 10(7) cells of Ehrlich carcinoma ascites form. Namely, 50% of the mice survived more than 60 days when ineffective doses of 0.5 mg/kg of Mitomycin-C and 50 mg/kg of SMP-Fr. I-d were administered intraperitoneally once daily for 7 days. SMP-Fr. I-d was found to be virtually non-toxic even in a dose of 1,000 mg/kg intraperitoneally in mice.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D008351:Mannans / Q000627:therapeutic use*; D051379:Mice; D008937:Mitomycins / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use*; D012441:Saccharomyces cerevisiae
D008351:Mannans; D008937:Mitomycins; D011134:Polysaccharides